Works matching DE "POLY(ADP-ribose) polymerase"
Results: 1089
PARP Inhibitors: What We Know and What We Have Yet to Know.
- Published in:
- Oncology (08909091), 2010, v. 24, n. 1, p. 62
- By:
- Publication type:
- Article
Inhibition of Poly(ADP)-Ribose Polymerase as a Therapeutic Strategy for Breast Cancer.
- Published in:
- Oncology (08909091), 2010, v. 24, n. 1, p. 55
- By:
- Publication type:
- Article
Capturing a Pentacyclic Fragment‐Based Library Derived from Perophoramidine: Their Design, Synthesis and Evaluation as Anticancer Compounds by DNA Double‐Strand Breaks (DSB) and PARP‐1 Inhibition.
- Published in:
- Chemistry - A European Journal, 2022, v. 28, n. 63, p. 1, doi. 10.1002/chem.202202405
- By:
- Publication type:
- Article
Poly(ADP-ribosyl)ation of proteins and germ cell development in hyperthyroid rat testes.
- Published in:
- Molecular & Cellular Biochemistry, 2009, v. 323, n. 1/2, p. 119
- By:
- Publication type:
- Article
Disease-causing mutations associated with bestrophinopathies promote apoptosis in retinal pigment epithelium cells.
- Published in:
- Graefe's Archive of Clinical & Experimental Ophthalmology, 2020, v. 258, n. 10, p. 2251, doi. 10.1007/s00417-020-04636-5
- By:
- Publication type:
- Article
Stilbene Derivatives from the Leaves and Stems of Bletilla striata and their Cytotoxicity and Autophagy Activity.
- Published in:
- Chemistry of Natural Compounds, 2021, v. 57, n. 3, p. 462, doi. 10.1007/s10600-021-03388-w
- By:
- Publication type:
- Article
Poly (ADP-ribose) polymerase inhibitor 3-methoxybenzamide enhances in vitro plant growth, microtuberization, and transformation efficiency of blue potato (Solanum tuberosum L. subsp. andigenum).
- Published in:
- In Vitro Cellular & Developmental Biology Plant, 2020, v. 56, n. 6, p. 833, doi. 10.1007/s11627-020-10086-9
- By:
- Publication type:
- Article
A New Approach for Studying Poly(ADP-Ribose) Polymerase Inhibitors Using Permeabilized Adherent Cells.
- Published in:
- Biochemistry (00062979), 2024, v. 89, n. 9, p. 1619, doi. 10.1134/S0006297924090086
- By:
- Publication type:
- Article
Study of Interaction of the PARP Family DNA-Dependent Proteins with Nucleosomes Containing DNA Intermediates of the Initial Stages of BER Process.
- Published in:
- Biochemistry (00062979), 2022, v. 87, n. 4, p. 331, doi. 10.1134/S0006297922040034
- By:
- Publication type:
- Article
PARPi Decreased Primary Ovarian Cancer Organoid Growth Through Early Apoptosis and Base Excision Repair Pathway.
- Published in:
- Cell Transplantation, 2023, v. 32, p. 1, doi. 10.1177/09636897231187996
- By:
- Publication type:
- Article
Single-particle analysis of full-length human poly(ADP-ribose) polymerase 1.
- Published in:
- Biophysics & Physicobiology, 2019, v. 16, n. 1, p. 59, doi. 10.2142/biophysico.16.0_59
- By:
- Publication type:
- Article
TOP BP1 regulates RAD51 phosphorylation and chromatin loading and determines PARP inhibitor sensitivity.
- Published in:
- Journal of Cell Biology, 2016, v. 212, n. 3, p. 281, doi. 10.1083/jcb.201507042
- By:
- Publication type:
- Article
Invasive bilateral breast cancer and high grade serous ovarian cancer with BRCA1-germline mutation and brainstem metastasis under PARP inhibitors.
- Published in:
- Archive of Clinical Cases, 2019, v. 6, n. 3, p. 69, doi. 10.22551/2019.24.0603.10156
- By:
- Publication type:
- Article
Second primary breast cancer during PARP inhibitor treatment of somatic BRCA mutant ovarian cancer – a case report.
- Published in:
- Oncolog-Hematolog, 2023, n. 63, p. 27
- By:
- Publication type:
- Article
Neoadjuvant treatment in triple-negative breast cancer.
- Published in:
- Oncolog-Hematolog, 2020, n. 52, p. 40
- By:
- Publication type:
- Article
Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors.
- Published in:
- Vaccines, 2021, v. 9, n. 10, p. 1148, doi. 10.3390/vaccines9101148
- By:
- Publication type:
- Article
CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer.
- Published in:
- Molecular & Cellular Oncology, 2020, v. 7, n. 6, p. 1, doi. 10.1080/23723556.2020.1805256
- By:
- Publication type:
- Article
Targeting CARM1 in ovarian cancer with EZH2 and PARP inhibitors.
- Published in:
- Molecular & Cellular Oncology, 2020, v. 7, n. 4, p. 1, doi. 10.1080/23723556.2020.1760675
- By:
- Publication type:
- Article
miR-155-5p 增强卵巢癌细胞 UWB1.289 对 PARP 抑制剂的敏感性.
- Published in:
- Progress in Modern Biomedicine, 2022, v. 22, n. 18, p. 3420, doi. 10.13241/j.cnki.pmb.2022.18.004
- By:
- Publication type:
- Article
氟苯达唑对人急性髓系白血病 HL-60 细胞的增殖抑制作用研究.
- Published in:
- Progress in Modern Biomedicine, 2020, v. 20, n. 4, p. 648, doi. 10.13241/j.cnki.pmb.2020.04.010
- By:
- Publication type:
- Article
MicroRNA-577 inhibits cardiomyocyte apoptosis induced by myocardial infarction via targeting PARP1.
- Published in:
- European Review for Medical & Pharmacological Sciences, 2019, v. 23, n. 21, p. 9566
- By:
- Publication type:
- Article
Inhibition of PARP overactivation protects acute kidney injury of septic shock.
- Published in:
- European Review for Medical & Pharmacological Sciences, 2018, v. 22, n. 18, p. 6049
- By:
- Publication type:
- Article
Development of an Environment-Friendly and Electrochemical Method for the Synthesis of an Oxadiazole Drug-Scaffold That Targets Poly(ADP-Ribose)Polymerase in Human Breast Cancer Cells.
- Published in:
- Catalysts (2073-4344), 2023, v. 13, n. 8, p. 1185, doi. 10.3390/catal13081185
- By:
- Publication type:
- Article
5-Aminoisoquinolinone, a PARP-1 Inhibitor, Ameliorates Immune Abnormalities through Upregulation of Anti-Inflammatory and Downregulation of Inflammatory Parameters in T Cells of BTBR Mouse Model of Autism.
- Published in:
- Brain Sciences (2076-3425), 2021, v. 11, n. 2, p. 249, doi. 10.3390/brainsci11020249
- By:
- Publication type:
- Article
Neuroprotective Effects of Activated Protein C Involve the PARP/AIF Pathway against Oxygen-Glucose Deprivation in SH-SY5Y Cells.
- Published in:
- Brain Sciences (2076-3425), 2020, v. 10, n. 12, p. 959, doi. 10.3390/brainsci10120959
- By:
- Publication type:
- Article
iNOS-Produced Nitric Oxide from Cancer Cells as an Intermediate of Stemness Regulation by PARP-1 in Colorectal Cancer.
- Published in:
- Biomolecules (2218-273X), 2025, v. 15, n. 1, p. 125, doi. 10.3390/biom15010125
- By:
- Publication type:
- Article
Poly(ADP-Ribose) Polymerase (PARP) Inhibitors for Cancer Therapy: Advances, Challenges, and Future Directions.
- Published in:
- Biomolecules (2218-273X), 2024, v. 14, n. 10, p. 1269, doi. 10.3390/biom14101269
- By:
- Publication type:
- Article
Radiosensitizing Effect of PARP Inhibition on Chondrosarcoma and Chondrocyte Cells Is Dependent on Radiation LET.
- Published in:
- Biomolecules (2218-273X), 2024, v. 14, n. 9, p. 1071, doi. 10.3390/biom14091071
- By:
- Publication type:
- Article
Combination Treatment Strategies to Overcome PARP Inhibitor Resistance.
- Published in:
- Biomolecules (2218-273X), 2023, v. 13, n. 10, p. 1480, doi. 10.3390/biom13101480
- By:
- Publication type:
- Article
The Role of Poly(ADP-ribose) Polymerase 1 in Nuclear and Mitochondrial Base Excision Repair.
- Published in:
- Biomolecules (2218-273X), 2023, v. 13, n. 8, p. 1195, doi. 10.3390/biom13081195
- By:
- Publication type:
- Article
Inherited Retinal Degeneration: Towards the Development of a Combination Therapy Targeting Histone Deacetylase, Poly (ADP-Ribose) Polymerase, and Calpain.
- Published in:
- Biomolecules (2218-273X), 2023, v. 13, n. 4, p. 581, doi. 10.3390/biom13040581
- By:
- Publication type:
- Article
Metabolic Activation of PARP as a SARS-CoV-2 Therapeutic Target—Is It a Bait for the Virus or the Best Deal We Could Ever Make with the Virus? Is AMBICA the Potential Cure?
- Published in:
- Biomolecules (2218-273X), 2023, v. 13, n. 2, p. 374, doi. 10.3390/biom13020374
- By:
- Publication type:
- Article
Effects of the PARP Inhibitor Olaparib on the Response of Human Peripheral Blood Leukocytes to Bacterial Challenge or Oxidative Stress.
- Published in:
- Biomolecules (2218-273X), 2022, v. 12, n. 6, p. 788, doi. 10.3390/biom12060788
- By:
- Publication type:
- Article
LRRK2 inhibition potentiates PARP inhibitor cytotoxicity through inhibiting homologous recombination‐mediated DNA double strand break repair.
- Published in:
- Clinical & Translational Medicine, 2021, v. 11, n. 3, p. 1, doi. 10.1002/ctm2.341
- By:
- Publication type:
- Article
Editorial: Circulating biomarkers in prostate cancer.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.1365353
- By:
- Publication type:
- Article
Targeting the DNA damage response in hematological malignancies.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.1307839
- By:
- Publication type:
- Article
A real-world study of PARP inhibitors in 75 patients with platinum-sensitive recurrent ovarian cancer from China.
- Published in:
- Frontiers in Oncology, 2024, p. 01, doi. 10.3389/fonc.2023.1300199
- By:
- Publication type:
- Article
PLK1 and PARP positively correlate in Middle Eastern breast cancer and their combined inhibition overcomes PARP inhibitor resistance in triple negative breast cancer.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2023.1286585
- By:
- Publication type:
- Article
Polyadenosine diphosphateribose polymerase inhibitors: advances, implications, and challenges in tumor radiotherapy sensitization.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1295579
- By:
- Publication type:
- Article
Long-term complete response with third-line PARP inhibitor after immunotherapy in a patient with triple-negative breast cancer: a case report.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1214660
- By:
- Publication type:
- Article
Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1175617
- By:
- Publication type:
- Article
Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1158981
- By:
- Publication type:
- Article
PARP inhibitors in metastatic prostate cancer.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1159557
- By:
- Publication type:
- Article
Combined treatment of disulfiram with PARP inhibitors suppresses ovarian cancer.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1154073
- By:
- Publication type:
- Article
Case report: A de novo ERBB3 mutation develops in a gallbladder cancer patient carrying BRCA1 mutation after effective treatment with olaparib.
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2023.1078388
- By:
- Publication type:
- Article
PARP inhibitor-related haemorrhages: What does the real-world study say?
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2023.1070343
- By:
- Publication type:
- Article
PARP inhibitors in the treatment of ARID1A mutant ovarian clear cell cancer: PI3K/Akt1- dependent mechanism of synthetic lethality.
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2023.1124147
- By:
- Publication type:
- Article
DNA repair deficiency as circulating biomarker in prostate cancer.
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2023.1115241
- By:
- Publication type:
- Article
Association of apoptosis-related microsatellite polymorphisms on chromosome 1q in Taiwanese systemic lupus erythematosus patients.
- Published in:
- Clinical & Experimental Immunology, 2006, v. 143, n. 2, p. 281, doi. 10.1111/j.1365-2249.2005.02984.x
- By:
- Publication type:
- Article
Cold atmospheric plasma for breast cancer treatment: what next?
- Published in:
- Medical Gas Research, 2025, v. 15, n. 1, p. 110, doi. 10.4103/mgr.MEDGASRES-D-24-00043
- By:
- Publication type:
- Article